A groundbreaking advancement from the University of Manchester promises to revolutionize the production of Lenacapavir, a highly effective long-acting HIV capsid inhibitor. Researchers at the Manchester Institute of Biotechnology (MIB) have engineered a biocatalytic process that slashes manufacturing costs and environmental impact, paving the way for broader global access to this life-saving drug. This innovation highlights the pivotal role of UK higher education in addressing global health challenges through sustainable biotechnology.
Lenacapavir, marketed as Sunlenca for treatment and Yeztugo for pre-exposure prophylaxis (PrEP), disrupts the HIV-1 capsid—the protein shell protecting the virus's genetic material. Administered as a twice-yearly subcutaneous injection, it offers near-complete protection against HIV acquisition, with trials like PURPOSE 1 showing 100% efficacy in cisgender women. Yet, its complex synthesis has limited scalability in resource-poor settings, where over 40 million people live with HIV and 1.3 million new infections occur annually.
🧬 The Manufacturing Challenge for Lenacapavir
Traditional production of Lenacapavir relies on multi-step chemical synthesis to assemble four key building blocks, including a sterically demanding chiral amine core. This core's precise three-dimensional structure is crucial for the drug's potency, but chemical routes are lengthy, generate waste, and demand expensive reagents and purification steps. High costs—up to thousands per patient-year in high-income markets—hinder generics for low- and middle-income countries (LMICs), despite voluntary licensing deals targeting $40 annual pricing from 2027.
With HIV disproportionately affecting LMICs (over 90% of cases), affordable manufacturing is essential. Current chemical processes limit supply, exacerbating access gaps where daily PrEP adherence remains low due to pill fatigue.
The Biocatalytic Innovation
Led by Professors Nick Turner and Anthony P. Green, Manchester researchers developed a bespoke aminotransferase (ATA) enzyme via directed evolution. Starting from a Ruegeria sp. TM1040 ATA with zero activity on the target ketone substrate, they employed 'substrate walking'—iteratively screening variants on increasingly similar substrates—to access the bulky precursor.
After eight evolution rounds and screening over 12,000 variants, ten mutations reshaped the active site for optimal fit. The final enzyme achieves >98% conversion, >90% isolated yield, and >99% enantiomeric excess (ee)—industrial benchmarks. X-ray crystallography confirmed structural changes, validating the design.
Step-by-Step: How the Engineered Enzyme Works
- Substrate Preparation: The ketone precursor, a challenging building block due to steric hindrance, is supplied with an amine donor like isopropylamine.
- Enzymatic Reductive Amination: The ATA catalyzes transfer of the amine group, forming the chiral (S)-amine with high stereoselectivity.
- Process Conditions: Operates at mild temperatures (30-40°C), neutral pH, aqueous media—reducing energy and solvent use.
- Purification: Simple extraction yields pure product, minimizing waste.
- Scale-Up: Tested under industrial conditions; robust stability supports biomanufacturing.
This replaces 4-6 chemical steps with one enzymatic reaction, cutting time from weeks to days.
Greener Chemistry: Environmental Wins
Biocatalysis aligns with green chemistry principles: fewer solvents, no toxic metals, recyclable enzyme. Traditional synthesis generates hazardous waste; this method uses water-based reactions, slashing carbon footprint. Manchester's approach supports UN SDG 12 (Responsible Production), mirroring their work on PET plastic recycling enzymes.
Prof. Green notes: “Biocatalysis offers a sustainable way to make complex molecules... helping lower costs and broaden access.”
Cost Reduction and Economic Implications
By streamlining synthesis, the enzyme could drop Lenacapavir production to $25-40/person/year at scale—1/1000th of US list prices. Gates Foundation funding aids translation to generics for 120 LMICs. UK biotech firms like Prozomix offer free enzyme samples, accelerating adoption.
For UK pharma, this bolsters competitiveness; Manchester's MIB exemplifies translational research, with spin-outs commercializing enzymes.
Manchester's Biotech Powerhouse
The MIB, home to Turner (emeritus expert in biocatalysis) and Green (ERC grantee, enzyme design leader), pioneers industrial biotech. Their portfolio includes molnupiravir (COVID antiviral) enzymes. Funded by BBSRC, EPSRC, this Lenacapavir work showcases UK higher ed's global impact.
Read the full JACS paper
Publication and Peer Validation
Published April 10, 2026, in J. Am. Chem. Soc., the study details evolution, kinetics (improved kcat/Km), and crystal structure (PDB code forthcoming). Metrics rival chemical catalysts, with process robustness confirmed industrially.
Broader Impact on HIV Eradication
With 39M adults living with HIV (UNAIDS 2024), Lenacapavir's PrEP efficacy could avert millions of infections. Cheaper production supports WHO 95-95-95 targets. UK universities like Manchester drive this via open innovation.
UK Higher Education's Role in Global Health
Manchester exemplifies Russell Group leadership in biotech. Initiatives like ICED foster enzyme engineering talent. Amid funding pressures, such breakthroughs justify investment in UK research infrastructure.
Photo by Nibin Matteo Dani on Unsplash
Future Horizons: Scale-Up and Beyond
Next: industrial biomanufacturing trials with partners. Potential for other drugs. MIB eyes plastic degradation, biofuels—positioning Manchester as green chemistry hub. For careers, explore MIB opportunities.
This Manchester innovation not only advances HIV fight but underscores higher ed's societal value.